Piper Sandler Maintains Overweight on Turnstone Biologics, Lowers Price Target to $3.75
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler has maintained an Overweight rating on Turnstone Biologics but significantly lowered the price target from $20 to $3.75.
August 19, 2024 | 4:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Piper Sandler has maintained an Overweight rating on Turnstone Biologics but significantly lowered the price target from $20 to $3.75.
The significant reduction in the price target from $20 to $3.75 suggests a negative outlook on the stock's potential performance, despite maintaining an Overweight rating. This could lead to a short-term decline in the stock price as investors react to the lowered expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100